Tocilizumab is a common treatment for rheumatoid arthritis (RA) patients with comorbid conditions or obesity and is effective irrespective of comorbidity burden or obesity status, according to a study.
Spinal manipulative therapies such as spinal manipulation and spinal mobilization did not seem effective for the management of mild-to-moderate chronic low back pain (LBP) in young adults, the RELIEF* trial has shown.
More than half of rheumatoid arthritis (RA) patients achieving low disease activity on long-term methotrexate (MTX) remain flare-free following its withdrawal, as shown in a study. The use of a higher MTX dose to preserve low disease activity is predictive of disease flare after discontinuation.
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.
Higher serum uric acid (UA) levels appear to be protective against vertebral fracture among elderly men, whereas excessive reduction of serum UA using urate-lowering medications confers a risk increase, a study has shown.